Updated analysis of a phase II trial in 436 patients with unfavourable cancer of unknown primary controlled after induction chemotherapy: molecularly guided therapy improved median PFS vs continued chemotherapy (6.1 vs 4.4 months; HR 0.75); OS gain non-significant (HR 0.79).
RCTn = 436
Krämer et al. Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study